Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.62 |
| ▸ | ESR1 | P03372 | 4/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.62 |
| ▸ | SHBG | P04278 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 7/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gestadienol SCHEMBL931512 | 0.82 | AR (0.65) | PGRLMNACYP3A4CYP2C19NR3C1 | |
| SCHEMBL5974395 | 0.81 | PGR (0.59) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| SCHEMBL4210007 | 0.81 | PGR (0.63) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| SCHEMBL11644759 | 0.81 | PGR (0.58) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| SCHEMBL11809654 | 0.79 | PGR (0.64) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| SCHEMBL11680779 | 0.79 | PGR (0.47) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| SCHEMBL984935 | 0.78 | PGR (0.57) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| Norethindrone SCHEMBL24476231 | 0.77 | CYP3A4 (1.00) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| Norethindrone SCHEMBL14074493 | 0.77 | CYP3A4 (1.00) | PGRLMNACYP3A4ABCB11CYP2C19 | |
| Norethindrone SCHEMBL23390 | 0.77 | CYP3A4 (1.00) | PGRLMNACYP3A4ABCB11CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204497-A1 | Process For The Preparation of 7 alpha-Methylsteroids | N.V. ORGANON | 2010-08-12 | — | — | US | disclosed |
| EP-1470151-B1 | PROCESS FOR THE PREPARATION OF 7-ALPHA-METHYLSTEROIDS | ORGANON NV (NL) | 2009-12-30 | — | — | EP | disclosed |
| EP-1237904-B1 | 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENS | AKZO NOBEL NV (NL) | 2006-02-08 | — | — | EP | disclosed |
| US-20050090476-A1 | Process for the preparation of 7alpha-methylsteroids | MERCK SHARP & DOHME B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| EP-1470151-A1 | PROCESS FOR THE PREPARATION OF 7-ALPHA-METHYLSTEROIDS | Akzo Nobel N.V. (NL) | 2004-10-27 | — | — | EP | disclosed |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | AKZO NOBEL N.V. (NL) | 2004-10-21 | — | — | US | disclosed |
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| US-6756366-B1 | 19-NORTESTOSTERONE DERIVATIVES; ORALLY ACTIVE; HIGH POTENCY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| US-20040059140-A1 | 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile | VAN DER LOUW JAPP (NL) | 2004-03-25 | — | — | US | disclosed |
| US-6706700-B2 | NOVEL STEROIDS CONTAINING A 14 BETA ,15 BETA - CYCLOPROPANE RING AND A 17 ALPHA HYDROXYMETHYL GROUP; MALE CONTRACEPTIVES | AKZO-NOBEL, N.V. (NL) | 2004-03-16 | — | — | US | disclosed |
| US-20030100543-A1 | Novel steroids containing a 14 beta ,15 beta - cyclopropane ring and a 17 alpha hydroxymethyl group; male contraceptives | N.V. ORGANON (NL) | 2003-05-29 | — | — | US | disclosed |
| US-20030087886-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2003-05-08 | — | — | US | disclosed |
| US-6541465-B2 | Delta 14 derivatives of 19- nortestosterone, useful for the preparation of a medicine for treating androgen insufficiency | AKZO NOBEL N.V. (NL) | 2003-04-01 | — | — | US | disclosed |
| WO-2002048169-A1 | 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE | AKZO NOBEL N.V. (NL) | 2002-06-20 | — | — | WO | disclosed |
| EP-1212345-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | Akzo Nobel N.V. (NL) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000059920-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | AKZO NOBEL N.V. (NL) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090476-A1 | Process for the preparation of 7alpha-methylsteroids | CYP17A1, CYP21A2, HSD17B7 | PGR 230/4885LMNA 2326/4885CYP3A4 69/4885 |
| US-20100204497-A1 | Process For The Preparation of 7 alpha-Methylsteroids | CYP17A1, CYP21A2, HSD17B7 | PGR 229/4885LMNA 2421/4885CYP3A4 71/4885 |
| US-20030087886-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | PGR 86/4885LMNA 2749/4885CYP3A4 99/4885 |
| US-20030100543-A1 | Novel steroids containing a 14 beta ,15 beta - cyclopropane ring and a 17 alpha hydroxymethyl group; male contraceptives | CYP17A1, HSD17B11, HSD17B7 | PGR 134/4885LMNA 3289/4885CYP3A4 160/4885 |
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | PGR 84/4885LMNA 2728/4885CYP3A4 100/4885 |
| US-20040059140-A1 | 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile | HSD17B11, CYP17A1, SHBG | PGR 11/4885LMNA 2074/4885CYP3A4 173/4885 |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | NR5A1, AR, SHBG | PGR 151/4885LMNA 2933/4885CYP3A4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.